MG
ACIU icon

Michael Gelband’s AC Immune ACIU Stock Holding History

Michael Gelband’s Portfolio ACIU Stock Details ACIU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,226
Closed -$101K – 2276
2021
Q1 		$101K Buy
+13,226
New +$94.4K ﹤0.01% 1978
2020
Q4 		– Sell
-16,100
Closed -$79K – 1903
2020
Q3 		$79K Buy
+16,100
New +$116K ﹤0.01% 1614
2020
Q1 		– Sell
-21,425
Closed -$183K – 1036
2019
Q4 		$183K Buy
+21,425
New +$143K ﹤0.01% 1352

Other funds holding ACIU

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 247.39% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $3.14B AUM 46.44% 1-Year Est. Return

Michael Gelband's ACIU Position: Q2 2021 in Review

Michael Gelband sold out of AC Immune (ACIU) in Q2 2021, closing a stake of 13,226 shares — an estimated $101K sold.

Michael Gelband first reported a position in ACIU in Q4 2019 and held it in 3 quarters. The position peaked at $183K in Q4 2019. 57 funds tracked by Wall St. Rank hold ACIU as of Q2 2021.

  • Michael Gelband reported no remaining AC Immune position as of Q2 2021 after selling out during the quarter.
  • Michael Gelband sold 13,226 AC Immune shares in Q2 2021, an estimated $101K.
  • Michael Gelband first reported a position in AC Immune in Q4 2019 and held it in 3 quarters.
  • Michael Gelband's AC Immune position peaked at $183K in Q4 2019.
  • 57 funds tracked by Wall St. Rank held AC Immune as of Q2 2021.

Based on ExodusPoint Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.